IngredientesLa proteína quinasa activada por AMP (AMPK) es una enzima central de detección de energía que se encuentra en cada célula del cuerpo. Actúa como un interruptor maestro metabólico, regulando cómo las células usan y generan energía. La AMPK se activa cuando los niveles de energía celular son bajos—específicamente cuando la proporción de monofosfato de adenosina (AMP) a trifosfato de adenosina (ATP) aumenta—como durante el ejercicio, la restricción calórica, el ayuno o el estrés metabólico. Una vez activada, la AMPK inicia una cascada de procesos diseñados para restaurar el equilibrio energético aumentando la producción de energía y disminuyendo el gasto de energía.
Las funciones clave de la AMPK incluyen:
Debido a su amplia influencia sobre el metabolismo, la AMPK se ha convertido en un objetivo de gran interés en los campos de la longevidad, el control del peso, los trastornos metabólicos y la prevención de enfermedades crónicas. La activación de la AMPK se ha vinculado a un riesgo reducido de diabetes tipo 2, enfermedades cardiovasculares, obesidad y algunos cánceres. También está implicada en el apoyo a la salud cerebral, la función mitocondrial y la extensión de la vida útil, especialmente cuando se activa a través de factores dietéticos y de estilo de vida.
La activación de la AMPK puede estimularse de forma natural mediante el ayuno intermitente, el ejercicio, la restricción calórica y la ingesta de ciertos nutracéuticos y compuestos herbales, como la berberina, el resveratrol, la quercetina, el ácido alfa-lipoico, las catequinas del té verde (EGCG) y la curcumina.
Uso Histórico:
La AMPK como objetivo molecular fue identificada y estudiada extensamente solo a finales del siglo XX, y su papel bioquímico detallado ha sido dilucidado a través de la biología molecular moderna y la investigación metabólica. Como tal, la AMPK no tiene historia directa en la medicina herbal tradicional ni en los sistemas de curación premodernos.
Sin embargo, muchas sustancias naturales y prácticas conocidas por activar la AMPK han sido utilizadas durante mucho tiempo en la medicina tradicional para equilibrar el azúcar en sangre, apoyar la pérdida de peso, mejorar la vitalidad y promover la longevidad. Por ejemplo:
Del mismo modo, el ayuno y la moderación dietética fueron elementos esenciales de los sistemas de salud tradicionales—ampliamente practicados en las filosofías griega, persa y oriental—para mejorar la claridad mental, la digestión y la disciplina espiritual, apoyando inadvertidamente vías que ahora se sabe que involucran la activación de la AMPK.
En la medicina integrativa moderna, la AMPK es considerada un regulador metabólico central—una puerta de entrada biológica a la reparación celular, el envejecimiento saludable y la eficiencia energética. Ejemplifica cómo la ciencia moderna continúa descubriendo la base molecular de las prácticas de salud antiguas, validando enfoques de estilo de vida y herbales que han sido utilizados durante mucho tiempo para mejorar la salud y la resiliencia.
Condiciones de salud que ginkgo biloba puede ayudar a apoyar.
Ginkgo biloba extract (standardized as EGb 761) has well-documented antioxidant properties supported by both mechanistic and human clinical evidence. Its flavonoid glycosides and terpene lactones scavenge reactive oxygen species (ROS), upregulate endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase), and activate the Nrf2 pathway. Clinical trials in humans—including patients with mild cognitive impairment—have recorded measurable increases in blood antioxidant biomarkers following EGb 761 administration. The antioxidant mechanism is considered a key contributor to its documented benefits in cerebrovascular and neurodegenerative conditions.
Ginkgo biloba (EGb 761 standardized extract) has shown anxiolytic activity in clinical trials, primarily in patients with cognitive impairment, where it reduced anxiety and depression symptoms significantly vs. placebo. Preclinical studies in rodents demonstrate anxiolytic effects via ginkgolide-A. It modulates monoaminergic neurotransmission, inhibits norepinephrine reuptake, and has anti-inflammatory effects.
Ginkgo biloba standardized extract (EGb 761) improves arterial endothelial function, reduces platelet-activating factor activity, inhibits leukocyte adhesion to injured arteries, and improves microcirculation. Controlled clinical trials demonstrate efficacy in peripheral arterial disease. A 2025 PubMed-indexed review confirmed its anti-inflammatory vascular activity as an anti-atherosclerotic nutraceutical.
Ginkgo biloba extract inhibits platelet-activating factor (PAF), a potent trigger of asthmatic bronchoconstriction, via its ginkgolide B constituent. It has been studied in at least one RCT with asthma patients and inhibits PAF-induced bronchoconstriction and airway inflammation. A murine study confirmed ginkgolide B suppressed Th2 cytokines and eosinophilia via ERK/MAPK pathway inhibition.
Ginkgo biloba has been evaluated in multiple RCTs for ADHD in children, with results showing significant reductions in inattention and ADHD rating scale scores compared to placebo, though it is less effective than methylphenidate. A 2025 systematic review identified three qualifying RCTs, one of which (Shakibaei et al.) found 93.5% vs 58.6% response rates in treated vs placebo groups.
Ginkgo biloba leaf extract has established neuroprotective and microcirculation-enhancing properties relevant to Bell's palsy, which involves ischemic/inflammatory compression of the facial nerve. Life Extension's Bell's palsy protocol identifies ginkgo as potentially beneficial for nerve cell function. A study referenced in PubMed (PMID 23021527) evaluated ginkgo's effect on recovery after facial nerve injury.
Ginkgo biloba contains ginkgolides that inhibit platelet-activating factor (PAF), reducing platelet aggregation. A 2025 PLoS ONE analysis found ginkgo biloba interactions were significantly associated with bleeding risk (OR 1.08, p<0.001) and a large chart review (n=807,399) found its combination with warfarin increases major bleeding risk. Evidence on standalone antiplatelet efficacy in controlled trials is mixed.
Ginkgo biloba extract has been examined for cardiovascular effects including blood pressure modulation, largely through its vasodilatory and PAF-antagonist mechanisms. Some clinical evidence suggests modest effects on vascular tone. However, the evidence base for blood pressure specifically is not conclusive, and ginkgo is not recognized by major guidelines as a blood pressure intervention.
Ginkgo biloba is one of the most extensively studied herbs for cognitive function, with a long history of use in Traditional Chinese Medicine for mental clarity. Standardized extracts (24% flavone glycosides, 6% terpene lactones) enhance cerebral blood flow, inhibit platelet-activating factor, and act as antioxidants. Multiple RCTs and meta-analyses support improvements in attention, memory, and processing speed in adults with cognitive impairment and age-related cognitive decline.
Ginkgo biloba extract is incorporated into validated oral anti-cellulite supplements and topical formulations. Its dimeric flavonoids inhibit phosphodiesterase, enhancing cAMP-mediated lipolysis and microvascular perfusion. A US patent specifically claims Ginkgo biloba dimeric flavonoids for cellulite treatment and a retrospective clinical trial (21 women, 90 days) showed anti-cellulite benefit.
Ginkgo biloba extract has well-documented effects on cerebral blood flow and mitochondrial function that may contribute to reduced mental fatigue. It is among the most extensively studied herbal supplements with numerous clinical trials showing improvements in cognitive performance, mental energy, and fatigue in both healthy adults and those with cognitive decline.
A 2022 systematic review and meta-analysis of 17 RCTs (1,104 participants) found that ginkgo biloba leaf extract (GBLE) significantly reduced serum CRP and IL-6 levels. Effects on CRP were strongest at baseline levels ≥3 mg/L and doses <500 mg/day. Evidence is promising but heterogeneous, with variability in study design and populations limiting firm conclusions.
Ginkgo biloba extract (GBE) has robust clinical evidence for improving blood flow across multiple vascular beds, including coronary, cerebral, cutaneous, and peripheral circulation. Multiple RCTs in CAD patients and healthy elderly adults demonstrate increased LAD blood flow and improved endothelium-dependent vasodilation. Nine double-blind RCTs in peripheral arterial insufficiency showed significantly increased pain-free and maximum walking distances alongside measurable plethysmographic blood-flow improvements.
Ginkgo biloba extract (EGb 761) has been extensively studied in human clinical trials for cognitive decline and healthy aging, making it one of the most researched botanical supplements in this domain. Evidence is mixed: large RCTs found no benefit for preventing dementia or slowing cognitive decline in cognitively normal older adults, while shorter RCTs at 240 mg/day show modest improvements in cognition and neuropsychiatric symptoms in mild cognitive impairment (MCI). An overview of ten systematic reviews concluded there is clear evidence supporting efficacy in MCI and dementia treatment, but the prevention question remains unresolved.
Ginkgo biloba extract (EGb761) has been evaluated as an adjunct for depression in multiple trials. A 2024 systematic review and meta-analysis (21 studies, n=2,074 patients) found significantly better Hamilton Depression Scale scores in ginkgo-treated patients at 4, 6, and 8 weeks versus controls. It is most studied as an adjunct in elderly and post-stroke depression.
A 2021 systematic review of 5 RCTs (475 participants) concluded that ginkgo biloba has limited positive effects on sexual function overall. Evidence for male erectile function specifically is weak, with preclinical data showing benefit after nerve injury but human trial results being inconsistent. The overall clinical evidence does not currently support ginkgo as an effective monotherapy for erectile dysfunction.
Ginkgo biloba extract (GBE) improves ocular microcirculation and has been studied for visual fatigue and glaucomatous visual field damage. A retrospective analysis (PMC3429325, n=332 patients) found GBE improved visual function in normal-tension glaucoma patients versus controls. Its flavone glycosides and terpenelactones support blood flow to the optic nerve and retina, which is relevant to fatigue from prolonged screen use.
Ginkgo biloba has been studied in pediatric ADHD with several RCTs and open-label trials showing improvements in attention and ADHD symptoms. A 2023 systematic review of herbal medicines for pediatric ADHD found several pieces of evidence supporting the efficacy of Ginkgo biloba. However, NCCIH notes current evidence is insufficient to formally recommend it for ADHD.
Ginkgo biloba leaf extract is among the most studied herbal nootropics, with multiple RCTs and meta-analyses demonstrating improvements in memory, attention, and processing speed, particularly in individuals with age-related cognitive decline. Its mechanisms include enhanced cerebral blood flow, antioxidant action, and inhibition of platelet-activating factor via ginkgolide B. German Commission E and ESCOP have approved standardized extract for cognitive disorders.
Ginkgo biloba extract (GBE) contains flavonoids and terpenoids with antioxidant and vasoactive properties that improve retinal and optic nerve blood flow. A Korean RCT (n=30, normal tension glaucoma) found 80 mg GBE twice daily significantly improved retinal blood flow vs. placebo. Small clinical trials also showed modest improvements in AMD-related vision and glaucoma-associated visual field damage.
Ginkgo biloba extract (EGb 761) has been studied in multiple clinical trials for glaucoma, particularly normal-tension glaucoma. Its standardized extract enhances ocular microcirculation, improves peripapillary blood flow, and has antioxidant properties relevant to optic nerve protection. A 2003 RCT found 120 mg/day improved visual field loss in low-pressure glaucoma patients.
Ginkgolide B, a terpene constituent of ginkgo biloba, has been studied as a PAF antagonist for migraine prophylaxis, particularly in young patients and women with migraine with aura. Small clinical trials show reductions in attack frequency and aura duration. Evidence is preliminary, with no large RCTs examining ginkgo as a monotherapy.
Ginkgo biloba has been used in Traditional Chinese Medicine for thousands of years and is extensively studied for cognitive aging. A PubMed narrative review (2022) synthesizes evidence linking ginkgo to memory improvement, cognitive protection, antioxidant effects, and cardiovascular support. Multiple RCTs in older adults demonstrate benefits for cognitive function and quality of life.
Ginkgo biloba extract (GBE) has been used in traditional Chinese medicine for vision and is recognized in ocular health for its antioxidant, anti-inflammatory, and vasodilatory properties that improve microcirculation in retinal capillaries. A randomized placebo-controlled trial of normal tension glaucoma patients showed improvement in pre-existing visual field damage with GBE. Scientific reviews confirm GBE's role in several degenerative eye diseases including AMD, though evidence is described as promising but not yet conclusive.
Ginkgo biloba (standardized extract EGb 761) is the most-studied herbal supplement for tinnitus and hearing loss. It is believed to improve inner-ear and cerebral blood circulation and protect against free radicals. European and American otolaryngology guidelines have recommended it for reducing tinnitus annoyance. Evidence from randomized controlled trials is mixed but a systematic review of five RCTs concluded standardized extract is an evidence-based treatment option for tinnitus.
Ginkgo biloba extract (GBE) has documented cardiovascular-relevant mechanisms — including vasorelaxation, inhibition of platelet aggregation, and improved coronary perfusion — supported by both laboratory and clinical data. However, the largest high-quality randomized trial (GEM Study, n=3,069) found no reduction in cardiovascular events or CVD mortality. Evidence is mixed overall, with clinical benefit most consistently demonstrated for peripheral arterial disease (intermittent claudication) rather than primary cardiac endpoints.
Ginkgo biloba leaf extract is one of the most extensively studied herbal nootropics, with a centuries-long history in traditional Chinese medicine. Its standardized extract (EGb 761) has been evaluated in numerous RCTs showing improvements in memory, attention, and processing speed, particularly in those with cognitive impairment. It acts as a cerebral vasodilator, antioxidant, and inhibitor of platelet-activating factor.
Ginkgo biloba has been used in TCM and has been clinically studied for sexual function, particularly in men with SSRI-induced sexual dysfunction. Multiple studies suggest it enhances penile blood flow via nitric oxide and platelet-activating factor antagonism. Clinical evidence is modest but consistent for pro-sexual effects in men.
Ginkgo biloba has been evaluated in clinical studies for lymphedema, with a study of 48 patients using Ginkor Fort (ginkgo extract) showing statistically significant improvement in limb heaviness in breast cancer-related arm lymphedema. It was also part of the Horsechestnut Complex used in the lymphoscintigraphy trial demonstrating significantly improved lymphatic drainage rates. Its ginkgolides and flavonoids protect capillary collagen integrity and improve microcirculation.
Ginkgo biloba extract contains flavone glycosides and terpene lactones (ginkgolides, bilobalide) with antioxidant and circulatory-enhancing properties relevant to AMD. A 6-month double-blind, placebo-controlled trial in 20 AMD patients (160 mg/day) reported improved visual acuity in the ginkgo group versus placebo. A Cochrane review identified only two small trials, concluding evidence is promising but insufficient to make definitive recommendations.
Ginkgo biloba extract (EGb) is one of the most extensively studied botanicals for memory and cognitive function, used traditionally in China and now globally. Evidence from RCTs is mixed: some trials in elderly patients with mild-to-moderate cognitive impairment show improvements in memory and cognitive scales, while the large GEM trial (n=3,069) found no significant effect in healthy older adults. It is best supported in populations with existing cognitive decline.
Ginkgo biloba leaf extract is one of the most studied herbal preparations for cognitive function, with traditional Chinese medicine use spanning centuries. Clinical trials show modest but consistent improvements in attention, working memory, and processing speed in healthy adults and those with age-related cognitive decline.
Ginkgo biloba, primarily via its terpene constituent ginkgolide B, has been studied for migraine with aura prophylaxis. Open clinical trials and preliminary studies suggest potential benefit, particularly for reducing aura frequency and duration. The 2019 PMC integrative migraine review identified positive results from older ginkgolide B studies.
Ginkgo biloba is one of the most researched herbal medicines for cognitive health, used in Traditional Chinese Medicine for thousands of years. Standardized extract EGb 761 improves cerebral blood flow, has potent antioxidant properties protecting brain cells, and shows moderate evidence for managing dementia symptoms.
Ginkgo biloba extract (EGb 761) contains ginkgolides, bilobalide, and flavone glycosides that improve peripheral nerve blood flow, reduce oxidative stress, and promote nerve cell survival. Listed in authoritative peripheral neuropathy evidence databases alongside ALC and methylcobalamin, it has traditional use in Chinese medicine for nerve conditions dating to the Ming Dynasty and scientific evidence for microvascular and neuroprotective benefits.
Ginkgo biloba's standardized extract (EGb761) modulates BDNF, stimulates Akt/mTOR neuroplasticity pathways, promotes neurite outgrowth, and improves cerebral microvascular function. A peer-reviewed 2017 Neural Plasticity review identified in vitro, in vivo, and clinical evidence for BDNF modulation. It has been used in Traditional Chinese Medicine for centuries.
Ginkgo biloba extract inhibits monoamine oxidase A and B, reducing catecholamine and serotonin degradation, and upregulates muscarinic acetylcholine receptors. Cochrane-referenced meta-analyses confirm cognitive and memory benefits in dementia, consistent with monoamine and cholinergic neurotransmitter support. Approved by German Commission E and WHO for age-related cognitive decline.
Ginkgo biloba extract (EGb761) has been studied in both animal models and clinical settings for Parkinson's disease. Animal studies consistently show neuroprotection of dopaminergic neurons via MAO-B inhibition and antioxidant activity. A clinical RCT assessed its efficacy in drug-induced parkinsonism. A 2013 systematic review of 10 controlled animal studies confirmed neuroprotective effects.
Ginkgo biloba extract has been evaluated in RCTs for PMS, with studies finding reductions in congestive and mood-related PMS symptoms. A 2009 RCT using standardised EGb 761 extract administered from day 16 of the cycle through day 5 of the next cycle showed significant reductions in PMS symptom severity versus placebo.
A double-blind, placebo-controlled RCT (Muir et al., Vasc Med 2002, PMID 12710841) found standardized ginkgo biloba extract at 360 mg/day for 10 weeks reduced Raynaud's attacks per week by 56% versus 27% for placebo in primary Raynaud's patients. Ginkgo's platelet-activating factor antagonism and vasodilatory mechanisms are proposed to attenuate episodic digital vasospasm. A Korean comparative RCT (KOARA study) also evaluated ginkgo against nifedipine for primary Raynaud's. It is the best-researched herbal remedy for Raynaud's according to Scleroderma & Raynaud's UK.
Ginkgo biloba extract has been used for peripheral vascular disorders including chronic venous insufficiency related to spider veins. Its ginkgolides and bilobalide exert vasodilatory, antioxidant, anti-inflammatory, and PAF-inhibitory effects. Pilot studies support its use in chronic venous disease, and it is commonly referenced alongside horse chestnut and bilberry for spider vein management.
Ginkgo biloba, particularly the standardized extract EGb 761, is the most extensively studied botanical for tinnitus. A 2011 systematic review found evidence of efficacy for EGb 761 from three RCTs in patients with primary tinnitus. However, a 2022 Cochrane review concluded that current evidence does not demonstrate benefit over placebo, and major guidelines (AAO-HNS, European Multidisciplinary) now recommend against its use. The mixed evidence base is partly attributed to differences in preparation quality.
Standardized Ginkgo biloba extract EGb 761 has demonstrated efficacy for vertigo and balance disorders in multiple randomized controlled trials and a 2023 meta-analysis. It improves vestibular compensation, reduces dizziness severity, and enhances balance training outcomes in age-related vestibular dysfunction. A 12-week multicenter RCT in 120 patients aged 60+ found clinically relevant improvement in vertigo and dizziness when EGb 761 was combined with balance training.
Ginkgo biloba has multiple double-blind, placebo-controlled clinical trial evidence in vitiligo. A 2003 RCT showed 40 mg three times daily for 6 months arrested disease spread in 20/25 active-group patients and induced marked repigmentation in 10. A 2011 open-label pilot trial confirmed halting of progression and 15% average VASI improvement at 12 weeks.
Ginkgo biloba has a long history in Traditional Chinese Medicine for improving vitality and circulation. Some research has explored its effects on exercise performance via improved blood flow and oxygen delivery, but clinical RCTs in athletic populations have produced inconsistent results. Evidence for athletic performance specifically is weak.
Ginkgo biloba is traditionally used for cognitive support and circulation enhancement, addressing brain fog, memory decline, and mood disturbances common in menopause. Listed in botanical reviews as used for menopausal cognitive and mood symptoms. Evidence is primarily for general cognitive and circulatory benefits with indirect application to menopause.
Ginkgo biloba has a long history of use in traditional Chinese medicine for supporting mental vitality, clarity, and emotional wellbeing across seasonal transitions. Modern interest stems from its monoamine-modulating properties and neuroprotective effects. However, dedicated clinical trials for seasonal mood support or seasonal affective disorder specifically are lacking.
Ginkgo biloba leaf extracts contain flavonoids and terpene lactones with immunomodulatory and limited antiviral properties. Traditional use in Chinese medicine for respiratory conditions spans centuries. Some in vitro studies show activity against influenza and HIV, but clinical evidence for viral immune response specifically is limited.
Sistemas corporales que ginkgo biloba puede ayudar a apoyar.
Volver